electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in …
Over the last 12 months, insiders at electroCore, Inc. have bought $284,612 and sold $0 worth of electroCore, Inc. stock.
On average, over the past 5 years, insiders at electroCore, Inc. have bought $586,931 and sold $5,960 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Goldberger Daniel S (Chief Executive Officer) — $990,349. Errico Thomas J. (director) — $30,595. GANDOLFO JOHN P (director) — $12,860.
The last purchase of 5,000 shares for transaction amount of $30,595 was made by Errico Thomas J. (director) on 2024‑08‑15.
2024-08-15 | director | 5,000 0.0788% | $6.12 | $30,595 | 0.00% | |||
2024-06-13 | director | 1,000 0.0156% | $6.43 | $6,430 | -2.21% | |||
2024-06-05 | Chief Executive Officer | 38,505 0.6218% | $6.43 | $247,587 | -5.43% | |||
2024-01-12 | Chief Financial Officer | 16,000 – | $0 | $0 | +5.44% | |||
2023-09-15 | Chief Executive Officer | 1,500 0.0246% | $5.55 | $8,333 | +7.96% | |||
2023-08-04 | Chief Executive Officer | 50,000 – | $0 | $0 | +32.64% | |||
2023-08-02 | Chief Executive Officer | 50,991 1.0559% | $4.35 | $221,811 | +37.10% | |||
2023-03-17 | Chief Executive Officer | 500 0.011% | $3.43 | $1,715 | +72.64% | |||
2023-03-16 | Chief Executive Officer | 500 0.0106% | $3.46 | $1,730 | +65.12% | |||
2023-03-15 | Chief Executive Officer | 500 0.0108% | $3.55 | $1,775 | +63.22% | |||
2023-03-14 | Chief Executive Officer | 500 0.011% | $3.73 | $1,865 | +58.99% | |||
2023-03-13 | Chief Executive Officer | 500 0.0113% | $3.86 | $1,930 | +56.51% | |||
2022-12-14 | Chief Executive Officer | 5,000 0.0071% | $0.35 | $1,749 | +2.65% | |||
2022-12-13 | director | 100,000 0.1382% | $0.33 | $33,330 | +4.36% | |||
2022-12-13 | Chief Executive Officer | 5,000 0.0068% | $0.33 | $1,649 | +4.36% | |||
2022-12-12 | Chief Executive Officer | 5,000 0.0068% | $0.32 | $1,590 | +7.70% | |||
2022-12-09 | Chief Executive Officer | 5,000 0.0067% | $0.30 | $1,499 | +12.38% | |||
2022-12-08 | Chief Executive Officer | 10,000 0.0143% | $0.28 | $2,777 | +29.55% | |||
2022-11-29 | director | 25,000 0.0353% | $0.33 | $8,253 | +6.31% | |||
2022-11-25 | director | 50,000 0.0678% | $0.31 | $15,735 | +7.03% |
Goldberger Daniel S | Chief Executive Officer | 249565 3.8075% | $11.07 | 18 | 0 | +21.16% |
Errico Thomas J. | director | 233818 3.5672% | $11.07 | 10 | 0 | +0.36% |
GANDOLFO JOHN P | director | 50704 0.7736% | $11.07 | 3 | 0 | <0.0001% |
POSNER BRIAN M | Chief Financial Officer | 22437 0.3423% | $11.07 | 4 | 1 | <0.0001% |
Merck Global Health Innovation Fund, LLC | 10 percent owner | 3346032 51.0487% | $11.07 | 1 | 0 |
Awm Investment Company Inc | $3.4M | 9.16 | 550,364 | 0% | +$0 | 0.52 | |
The Vanguard Group | $997,720.00 | 2.69 | 161,705 | +4.78% | +$45,528.44 | <0.0001 | |
Renaissance Technologies | $410,000.00 | 1.11 | 66,516 | +37.38% | +$111,567.14 | <0.01 | |
International Assets Investment Management Llc | $324,482.00 | 0.88 | 53,020 | +49.77% | +$107,834.27 | <0.01 | |
Geode Capital Management | $324,687.00 | 0.88 | 52,609 | +1.46% | +$4,678.15 | <0.0001 |